* Protagonist Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2024
* The Newark California California-based company is expected to report revenue of $1.667 million, according to the mean estimate from 6 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Protagonist Therapeutics Inc is for a loss of 62 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $51.50, above its last closing price of $46.76.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.57 -0.60 -0.50 Beat 16.9
Jan. 1 0001 0.53 1.19 3.26 Beat 173.1
Dec. 31 2023 0.03 -0.03 0.44 Beat 1,425.
3
Jan. 1 0001 -0.70 -0.69 -0.58 Beat 16.4
Jan. -0.65 -0.65 -0.68 Missed -5
1 0001
Mar. 31 2023 -0.77 -0.73 -0.67 Beat 7.8
Dec. 31 2022 -0.52 -0.64 -0.69 Missed -8.1
Sep. 30 2022 -0.86 -0.87 -0.64 Beat 26.3
This summary was machine generated November 2 at 04:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments